KAAG1 Human
Kidney-associated antigen 1, RU2 antisense gene protein, KAAG1, RU2AS, MGC78738.
Description
KAAG1 Human Recombinant fused with a 20 amino acid His tag at N-terminus produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 104 amino acids (1-84 a.a.) and having a molecular mass of 11.1kDa.
The KAAG1 is purified by proprietary chromatographic techniques.
Product Specs
Kidney-associated antigen 1, RU2 antisense gene protein, KAAG1, RU2AS, MGC78738.
MGSSHHHHHH SSGLVPRGSH MDDDAAPRVE GVPVAVHKHA LHDGLRQVAG PGAAAAHLPR WPPPQLAASR REAPPLSQRP HRTQGAGSPP ETNEKLTNPQ VKEK.
Product Science Overview
KAAG1 is primarily expressed in the testis and kidney . It is also found, albeit at lower levels, in the urinary bladder and liver . This protein is notable for its high expression in a variety of tumors, including melanomas, sarcomas, and colorectal carcinomas . The selective expression of KAAG1 in these tissues and tumors makes it a valuable target for research and potential therapeutic interventions.
The recombinant form of KAAG1 is produced using Escherichia coli (E. coli) as the expression system . This involves the insertion of the KAAG1 gene into the bacterial cells, which then produce the protein. The recombinant protein is typically fused with a His-tag at the N-terminus to facilitate purification . The resulting protein is purified using conventional chromatography techniques to achieve a purity level of over 90%, as determined by SDS-PAGE .
The recombinant KAAG1 protein consists of 84 amino acids and has a theoretical molecular weight of approximately 11.1 kDa . However, the observed molecular weight may vary due to post-translational modifications and other experimental factors . The protein is stored in a buffer containing 20 mM Tris-HCl (pH 8.0), 10% glycerol, and 0.1 M NaCl to maintain its stability .
KAAG1’s expression in a high proportion of tumors of various histologic origins makes it a promising candidate for cancer research. It is particularly relevant in the study of melanomas, sarcomas, and colorectal carcinomas . The protein’s selective expression in tumors and its ability to be internalized and co-localized with lysosomal markers make it an ideal target for antibody-drug conjugates (ADCs) . ADCs are a class of targeted cancer therapies that deliver cytotoxic agents directly to cancer cells, minimizing damage to healthy tissues.
